Skip to content

TRansmural hEaliNg Definition in CroHn's Disease (TRENCH 1)

TRansmural hEaliNg Definition in CroHn's Disease - The TRENCH1 Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05903066
Acronym
TRENCH 1
Enrollment
210
Registered
2023-06-15
Start date
2023-09-28
Completion date
2025-08-31
Last updated
2024-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn Disease

Keywords

IBD, CD

Brief summary

Multicenter prospective cross-sectional study of CD patients, its aim is the construction of an objective and reproducible system for evaluation of Transmural healing in Crohn's Disease (CD). Primary objective : Objective definition of depth or grade of transmural healing in relation to radiologic signs observed during Magnetic Resonance Enterography (MRE) in CD

Detailed description

Number of patients : 210 patients, in 14 sites (only one investigator per site), 15 patients per site, 5 patients per grade of transmural healing based on the appraisal of a local reader pair (a gastroenterologist and a radiologist). Recruitment period : 2 years Primary Endpoint : Objective definition of depth or grade of transmural healing in relation to radiologic signs observed during Magnetic Resonance Enterography (MRE) in CD Secondary Endpoints : * To analyze intra- and inter-observer variability of radiological findings. * To analyze intra- and inter-observer variability of TH definitions in CD.

Interventions

MRE performed as part of the standard of care follow up of the patient, the exam will be recorded for the study and analysed by central readers.

Sponsors

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* ≥ 18 years of age * Patient diagnosed with CD for more than 6 months with histological confirmation available in his medical record. * Indication for MRE based on routine clinical practice validated by the treating physician * Any CD treatment will be authorized, such as biologicals (infliximab, adalimumab, vedolizumab, ustekinumab…), or immunomodulators (azathioprine, 6-mercaptopurine, methotrexate…). * The subjects sign and date a written, informed consent form and any required privacy authorization prior to the initiation of the study. * A subject can be enrolled into the study only if the grade of TH (assessed by the LRP) corresponding to the subject is not already fulfilled.

Exclusion criteria

* Pregnancy during the study * People unable to give consent (because of their physical or mental state) * Absence of written consent * Ulcerative colitis or unclassified IBD * Specific postsurgical settings: ileoanal anastomosis, ileostomy or colostomy. * Less than 3 evaluable ileocolic segments or more than 3 resected ileocolonic segments (not counting ileocecal valve) * Severe obstructive symptoms * Symptomatic intra-abdominal abscess * Contraindication for MRI * Isolated perianal disease without luminal location * MRE images of poor quality, based on previously defined criteria

Design outcomes

Primary

MeasureTime frameDescription
Objective definition of depth or grade of transmural healing in relation to radiologic signs observed during Magnetic Resonance Enterography (MRE) in CDDay 1An index (depth of remission) or score (grade of remission) will be constructed through multiple linear or logistic mixed regression models.

Secondary

MeasureTime frameDescription
Intra- and inter-observer variability of lesions observed per segment during MRE in CDDay 1Variations in MRE readings images between the CR will be quantified through the Kappa coefficient for qualitative items and through the intraclass correlation coefficient for quantitative items.
Intra- and inter-observer variability of depth and grade of global transmural healing in CDDay 1Variations in MRE readings images between the CR will be quantified through the Kappa coefficient for qualitative items and through the intraclass correlation coefficient for quantitative items.

Countries

Belgium, France

Contacts

Primary ContactSophie GEYL
sophie.geyl@chu-limoges.fr+33 5 55 05 66 31
Backup ContactLaurent PEYRIN-BIROULET
peyrinbiroulet@gmail.com+33 3 83 15 36 61

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026